Dr Karl Kilgore speaks to ecancer at the 2019 ASH meeting in Orlando about the real-world use of CAR T-cell therapy in medicare patients with non-Hodgkin lymphoma.
He describes this study which investigated the costs, outcomes and healthcare utilisation in these patients before and after they received CAR T-cell therapy, as well as their demographic and clinical characteristics.
Dr Kilgore emphasises that the results of this study strongly show that older patients with co-morbidities can be successfully treated with this type of therapy
This program is funded in part via an independent grant from AbbVie. ecancer is editorially independent and there is no influence over content.
Read more about the study here.